The short version
Only one company currently supplies this market — there is no backup if it stumbles.
Market view
mirikizumab-mrkz
10 marketed package NDCs · 1 active manufacturer
Most dispensed: MIRIKIZUMAB 100 mg/mL · Injection, Solution · #1 syringe/carton / 2 ml in 1 syringe · MIRIKIZUMAB 100 mg/mL · Injection, Solution · #2 syringes/carton / 1 ml in 1 syringe
Same drug class
Other molecules FDA puts in Interleukin-23 Antagonist, with whether each is in shortage right now. Same class is not the same drug — substitution is a clinical decision, and this is a supply picture, not a recommendation.
Common questions
- Is Mirikizumab-mrkz in shortage right now?
- No. FDA does not currently list Mirikizumab-mrkz in shortage. This page is rebuilt every morning from FDA's shortage database, so a new posting appears here the day it is published.
- Who makes Mirikizumab-mrkz?
- 1 company has marketed Mirikizumab-mrkz in the last 30 days, according to the FDA NDC Directory. That is a thin market — if one stops making it, supply is at risk quickly. Every manufacturer and package is listed on this page.
Shortage reports for this molecule
- Planned discontinuation — Omvoh, Injection, 100 mg/1 mL (NDC 0002-8011-27)Dec 22, 2025
- Planned discontinuation — Omvoh, Injection, 100 mg/1 mL (NDC 0002-8870-27)Dec 22, 2025
All marketed products
Expand a strength to see its dosage forms, then package sizes, then each manufacturer and NDC. Click an NDC for its full detail page.